Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation

Arthritis Care and Research

Volumn 68, Issue 4, 2016, Pages 446-453

  Markusse, I M ^a   Dirven, L ^a   Han, K H ^b   Ronday, H K ^c   De Sonnaville, P B J ^d   Kerstens, P J S M ^e   Lems, W F ^f   Huizinga, T W J ^a   Allaart, C F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d Admiraal de Ruyter Hospital   (Netherlands)

^e Reade   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; DISEASE ACTIVITY SCORE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; PHYSICIAN ATTITUDE; POST HOC ANALYSIS; PROTOCOL COMPLIANCE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; SATISFACTION; TREAT TO TARGET PROTOCOL; ARTHRITIS, RHEUMATOID; ATTITUDE TO HEALTH; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; HEALTH PERSONNEL ATTITUDE; MULTICENTER STUDY; NETHERLANDS; ODDS RATIO; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGRAM EVALUATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATTITUDE OF HEALTH PERSONNEL; FEASIBILITY STUDIES; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NETHERLANDS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961958096     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22681     Document Type: Article

References (24)

1. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al., The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Rheum 2009; 60: 1222-31.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al., DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010; 69: 65-9.
3. Bakker MF, Jacobs JW, Welsing PM, Vreugdenhil SA, van Booma-Frankfort C, Linn-Rasker SP, et al., Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011; 70: 1099-103.
4. Heimans L, Wevers-de Boer KVC, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, et al., A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2014; 73: 1356-61.
5. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al., The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70: 1039-46.
6. Den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, et al., A non-inferiority trial of an attenuated combination strategy ("COBRA-light") compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014; 73: 1071-8.
7. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
8. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al., Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
9. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
10. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al., Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011; 70: 1999-2002.
11. Van Hulst LT, Creemers MC, Fransen J, Li LC, Grol R, Hulscher ME, et al., How to improve DAS28 use in daily clinical practice? A pilot study of a nurse-led intervention. Rheumatology (Oxford) 2010; 49: 741-8.
12. Littlejohn G, Roberts L, Arnold M, Bird P, Burnet S, de Jager J, et al., A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. Int J Rheum Dis 2013; 16: 532-8.
13. Fransen J, Moens H, Speyer I, van Riel PL., Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-8.
14. Pincus T, Segurado OG., Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006; 65: 820-2.
15. Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB., Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
16. Pincus T, Castrejon I, Bergman MJ, Yazici Y., Treat-to-target: not as simple as it appears. Clin Exp Rheumatol 2012; 30 Suppl: S10-20.
17. Pincus T, Sokka T., Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 731-4.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
19. Yazici Y, Bergman M, Pincus T., Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 2008; 35: 603-9.
20. Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al., Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64: 206-14.
21. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D., Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 857-64.
22. Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al., Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 2012; 14: R254.
23. Wolfe F, Michaud K., Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56: 2135-42.
24. Markusse IM, Akdemir G, Huizinga TW, Allaart CF., Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion. Clin Rheumatol 2014; 33: 1155-9.